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Abstract: The clinical management of cancer continues to be dominated by macroscopic 
surgical resection, radiotherapy, and cytotoxic drugs. The major challenge facing oncology is 
to achieve more selective, less toxic and effective methods of targeting disseminated tumors, 
a challenge oncolytic virotherapy may be well-placed to meet. Characterization of coxsackievirus 
A21 (CVA21) receptor-based mechanism of virus internalization and lysis in the last decade 
has suggested promise for CVA21 as a virotherapy against malignancies which overexpress those 
receptors. Preclinical studies have demonstrated proof of principle, and with the results of early 
clinical trials awaited, CVA21 may be one of the few viruses to demonstrate benefit for patients. 
This review outlines the potential of CVA21 as an oncolytic agent, describing the therapeutic 
development of CVA21 in preclinical studies and early stage clinical trials. Preclinical evidence 
supports the potential use of CVA21 across a range of malignancies. Malignant melanoma is 
the most intensively studied cancer, and may represent a “test case” for future development of 
the virus. Although there are theoretical barriers to the clinical utility of oncolytic viruses like 
CVA21, whether these will block the efficacy of the virus in clinical practice remains to be 
established, and is a question which can only be answered by appropriate trials. As these data 
become available, the rapid journey of CVA21 from animal studies to clinical trials may offer a 
model for the translation of other oncolytic virotherapies from laboratory to clinic.
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Introduction
Cancer continues to be a leading cause of death, accounting for 8.2 million deaths 
worldwide in 2012. Notwithstanding the combined efforts of public health initiatives; 
epidemiologists; and clinical, surgical and radiation oncologists, cancer is set to remain 
a leading cause of mortality with incidence projected to rise from an estimated 12 
million cases in 2012 to 22 million within the next twenty years.1 Traditionally, efforts 
have sought to exploit the rapid turnover of cancer cells using cytotoxic chemotherapy 
and radiotherapy, and strategies which combine surgical resection with chemotherapy/
radiotherapy have been developed to confer the optimal prognosis for patients with 
solid tumors. Remarkable improvements have been made in some malignancies, such 
as breast cancer; however, for malignancies such as lung, brain, and pancreatic cancer 
little improvement in survival has been observed over recent years.2 Treatment of meta-
static cancer remains a largely palliative exercise, with no treatments definitively and 
significantly altering the natural history of the disease. Meanwhile, the cost and toxicity 
of treatment regimens, which often provide limited benefit, impose difficult decisions 
on health professionals and patients, particularly in advanced stages of the disease.
Oncolytic Virotherapy 2014:3submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
48
Bradley et al
The intractability of malignant disease and the heavy 
toll of treatment on quality of life have prompted innovative 
approaches. One such strategy is harnessing and adapting 
viruses, either naturally occurring or genetically modified, as 
oncolytic viruses (OVs) to lyse malignant cells and stimulate 
an antitumor immune response. Such an approach allows 
viruses to exploit the natural characteristics of malignant 
disease, sparing normal cells and avoiding the adverse effects 
often associated with chemotherapy. In addition, the immune 
stimulation associated with virus treatment may help to 
generate long-term immune control of cancer cell growth. 
However, to date, no oncolytic virotherapy has become part 
of standard anticancer therapy.
An emerging oncolytic virus, coxsackievirus A21 
(CVA21), may stand on the cusp of such practical clinical 
application, although researchers are still establishing the 
capabilities of this virus against malignancy. This review 
outlines the wider context of oncolytic virotherapy and 
describes current evidence supporting the use of CVA21 for 
the treatment of malignant disease. The barriers associated 
with clinical implementation of CVA21 and its development 
as a novel anticancer agent are also discussed.
Oncolytic viruses and virotherapy
The concept of utilizing viruses as cancer therapies is not 
new. The idea originated over a century ago, and virotherapy 
experimentation later gained popularity in the 1950s, when 
patients were treated with a variety of virus preparations.3 
Viruses are known to have tropisms which predispose them 
to infect specific cell types, and some naturally occur-
ring viruses preferentially replicate in tumor cells which, 
due to defective antiviral response mechanisms, are more 
susceptible than healthy cells. Their main mode of action 
within a tumor mass is thought to be through infiltration and 
replication, leading to destruction of tumor tissue/ oncolysis.4 
As well as direct oncolysis, OVs can also promote host 
antitumor immunity,5 and it is hoped that viral replication 
within the tumor, systemic dissemination, and the generation 
of antitumor immune priming could all be effective against 
widespread metastatic disease.
The advent of molecular techniques controlling transcrip-
tion and translation facilitated major advances in oncolytic 
virotherapy in the 1990s, using genetic modification to engi-
neer and deliver viruses with more specific antitumor effects.4 
Subsequently, two distinct strategies utilizing either naturally 
occurring OVs (eg, Newcastle-disease virus, reovirus, and 
CVA21), with inherent cytotoxicity against tumor cells, or 
genetically modified viruses (eg, adenovirus, vaccinia and 
herpes simplex virus), which are genetically engineered to 
selectively target tumor cells,6 were developed.
Since research into oncolytic virotherapy began in earnest 
in the 1990s, interest has been focused around a dozen or 
so OVs, with herpes simplex, measles, Newcastle-disease 
virus, reovirus, vaccinia, and adenovirus being the most 
well characterized.3 The first government approved oncolytic 
virotherapy was licensed by the People’s Republic of China 
in 2005 for the treatment of head and neck cancer, namely 
the genetically modified H101 adenovirus.7
Phase III trials remain to be conducted for almost all 
candidate OVs, although the results of some Phase I/II trials 
demonstrate grounds for optimism in this emerging field of 
oncology. Most significantly, a herpes simplex virus encoding 
granulocyte macrophage-colony stimulating factor (talimo-
gene laherparepvec or T-VEC) injected intratumorly led to 
regression of melanoma in eight of 50 patients in a Phase II 
study,8 and the consequent Phase III trial has recently been 
reported to have met its primary endpoint of durable response 
rate; overall survival data are still awaited. Equally encour-
aging is the observation that OVs so far appear to be safe, 
with Phase I studies suggesting large doses can be tolerated 
without dose-limiting toxicities.9
CVA21
CVA21 is an enterovirus and, in common with other members 
of the Picornaviridae family, is unenveloped and contains a 
positive-sense, single-stranded RNA genome, enclosed in 
an icosahedral capsid. The virus has been classified into two 
groups, A and B, based on their effects in murine models. 
Group A contains 23 serotypes that impact mainly on skeletal 
muscle while group B contains only 6 serotypes and affects a 
wider variety of tissue types. In humans, the virus is clinically 
significant as one of many organisms responsible for mild 
upper respiratory tract infections (coryza), spread by aerosol 
transmission,10,11 and as such, its clinical manifestation is 
indistinguishable from several other viruses.
Oncolytic CVA21 is manufactured commercially as CAV-
ATAK™ by Viralytics Limited (Sydney, NSW, Australia), 
and has been developed from the wild type Kuykendall 
strain. The receptor-based mechanisms of attachment and 
cell internalization have been extensively modeled and are 
well understood,12 and there is evidence that other group A 
serotypes of coxsackie could yield similar oncolytic poten-
tial.13 CVA21 infection is characterized by its interaction with 
the intercellular adhesion molecule-1 (ICAM-1, also termed 
CD54), which acts as the primary receptor for attachment 
and internalization, and decay-accelerating factor (DAF, or 
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CD55), a coreceptor acting as a secondary point of virus 
attachment.14
ICAM-1 is a cell surface glycoprotein that is expressed 
on various cell types including leukocytes, epithelial cells, 
and endothelial cells15 and has a number of immunological 
roles, including binding to leukocyte function-associated 
antigen 1 during adhesion of leucocytes to endothelial cells. 
The recruitment of ICAM-1 as a viral receptor is common 
among many of the Picornaviridae family of viruses. DAF 
is expressed ubiquitously on almost all cells, including 
erythrocytes, and its primary role is in regulating comple-
ment responses,14 but DAF is also targeted by several other 
enteroviruses, including serotypes of echovirus and coxsackie 
B virus. CVA21 attachment to DAF is not sufficient to infect 
host cells, as internalization is dependent on ICAM-1 expres-
sion; DAF is thought to act as a membrane concentration 
receptor, which accumulates virus at the cell surface, opti-
mizing viral entry via ICAM-1.16 Interestingly, a bioselected 
coxsackie variant has been produced that is solely dependent 
on DAF for both invasion and lysis.16 Variants with altered 
cell surface specificity may be of significance for tumors that 
overexpress DAF and/or underexpress ICAM-1. Although 
the expression of ICAM-1 and DAF are proposed to underpin 
the oncolytic properties of CVA21, it is possible that future 
investigations will uncover alternative mechanisms required 
for cancer-specific viral replication.
The production of such variants notwithstanding, the 
existence of CVA21 as a wild-type virus probably limits 
the prospects of deliberate manipulation or engineering.4 On 
the other hand, the virus’s ubiquity and well understood, albeit 
irksome, role in coryza, may represent significant advantages 
in terms of safety and achieving regulatory approval.
The promise of exploiting CVA21 preferentially to lyse 
cancer cells lies in the observation that the ICAM-1 and 
DAF receptors are overexpressed in various cancer cells, 
compared to nonmalignant tissue. This has been demon-
strated in melanoma, breast, colon, endometrial, head and 
neck, pancreatic, and lung cancers as well as in multiple 
myeloma and malignant glioma.17–21 Furthermore, increased 
expression of ICAM-1 on metastatic disease, and the role for 
ICAM-1 in metastasis formation,22–24 make CVA21 targeting 
of metastatic disease a particularly attractive strategy.
It is hoped that CVA21 will be effective as an oncolytic 
agent, both through direct invasion and lysis, and by stimu-
lation of host antitumor immune mechanisms; however, the 
immunogenic potential of CVA21 remains unknown, and 
investigations using relevant model systems are required 
to clarify the role of the immune system in the efficacy of 
CVA21 therapy.
Evidence supporting CVA21  
as a novel anticancer agent
Research into the potential use of CVA21 for a variety of 
malignancies is ongoing, spanning preclinical in vitro studies 
and Phase I/II clinical trials. These studies have investigated 
the efficacy of CVA21 in melanoma, multiple myeloma, 
breast, lung, and prostate cancer models, and key findings 
are summarized in Table 1.
Melanoma
Because melanoma is a malignancy with marked overexpres-
sion of ICAM-1 and DAF compared to normal cells,25 with 
lesions amenable to injection, studies of CVA21 in melanoma 
are the most advanced, and may come to be regarded as the 
“test case” proof-of-principle for the efficacy of CVA21. 
The characteristic upregulation of ICAM-1 in melanoma 
is well established; indeed, it has been considered a clini-
cally relevant marker of prognosis.22,24 In addition, a role for 
Table 1 Summary of preclinical studies with CVA21
Malignancy ICAM-1/DAF expression In vitro CVA21 sensitivity In vivo – decreased 
tumor burden
References
Melanoma Human cell lines and  
primary samples
Cytotoxic against human  
cell lines
SCiD mice – it, iv, and ip  
administration
22,24,26,27
Multiple myeloma Human cell lines, 15 MM and  
5 MGUS patient samples
Cytotoxic against human  
cell lines and primary samples
SCiD mice – it, iv administration 25,29
Breast cancer Human cell lines and primary  
samples
Cytotoxic against human  
cell lines
SCiD mice – iv administration 18,30,31
Prostate cancer Human cell lines and primary  
samples
Cytotoxic against iCAM-1  
positive human cell lines
SCiD mice – iv administration 32,33,34
Lung cancer NSCLC and SCLC human cell lines Cytotoxicity against human cell lines SCiD mice – it administration 35
Head and neck cancer Human cell lines or primary ND ND 36
Abbreviations: CVA21, coxsackievirus A21; DAF, decay-accelerating factor; iCAM-1, intercellular adhesion molecule-1; ip, intraperitoneal; it, intratumoral; iv, intravenous; 
MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; ND, not determined; NSCLC, non-small-cell lung cancer; SCID, severe combined 
immunodeficiency; SCLC, small cell lung cancer.
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ICAM-1 in the generation of metastases has been suggested, 
as it facilitates cell–cell interactions between malignant 
melanocytes and circulating lymphocytes and spread of the 
disease.26
Experiments published in 200427 established that upregu-
lation of ICAM-1 in melanoma could be exploited for CVA21 
therapy. These data used two human melanoma cell lines, 
one chemotherapy-resistant and one derived from primary 
melanoma, and demonstrated in vitro oncolysis. In vivo, the 
authors proceeded to show that mouse xenograft tumors were 
reduced when treated with CVA21 by  intratumoral, intrave-
nous, and intraperitoneal administration.26 Interestingly, the 
same group later demonstrated that other group A coxsackie 
viruses (13, 15, and 18) exhibited similar oncolytic properties 
and were not susceptible to neutralizing antibodies (NABs) 
against CVA21. This raises the prospect of a future “mul-
tivalent” approach, using different serotypes to overcome 
potential immunological barriers.13
CVA21 investigations have progressed to clinical trials, 
with Phase I safety trials being completed in 2009 and a 
Phase II (6 months) and extension trial (48 weeks) currently 
recruiting in the US. The Phase II trial (CALM [CAVATAK 
in Late stage Melanoma])28 is currently underway across 
nine sites in the US. The trial has a primary endpoint assess-
ing progression-free survival at 6 months as well as further 
assessments of safety. The trial’s investigators aim to include 
54 patients with unresectable stage IIIc-IV M1c melanoma, 
38 of whom have so far been recruited. Participants will be 
treated intratumorally on days 1, 3, 5, 8, and 21, then every 
3 weeks for an additional five injections. In addition, Phase I 
trials are currently in development to examine intravenous 
administration of CVA21 to solid tumors, including mela-
noma, as well as lung, prostate, and bladder cancers.
Multiple myeloma
A 2006 preclinical study sought to investigate CVA21-medi-
ated oncolysis, both in vitro and in vivo, in multiple myeloma. 
Flow cytometry first confirmed ICAM-1 and DAF expression 
in four multiple myeloma cell lines. In vitro, CVA21 caused 
oncolysis, and in vivo, tumor regression was observed in 
mouse xenografts, although toxicity was noted in these 
immunologically compromised mice, with development of 
hind limb paralysis after treatment.  Pathology demonstrated 
widespread myositis as well as complete tumor ablation.29
A further ex vivo study tested the virus against bone 
marrow samples derived from 15 patients (ten with multiple 
myeloma and five with monoclonal gammopathy of undeter-
mined significance). This study confirmed strong expression 
of ICAM-1 in the multiple myeloma cells compared to nor-
mal peripheral blood mononuclear cells. As for melanoma, 
preferential selectivity of CVA21 for myeloma, with greater 
lysis than control peripheral blood mononuclear cells, was 
found. Myeloma cell lines also supported greater virus repli-
cation while normal mononuclear cells were not productively 
infected.25 Finally, the researchers showed that CVA21 could 
purge malignant plasma cells from bone marrow samples of 
patients with malignant myeloma and monoclonal gammo-
pathy of undetermined significance, suggesting that CVA21 
could be used as a purging agent prior to autologous stem 
cell transplantation.25
Breast cancer
In common with melanoma, examination of surface markers 
on metastatic breast cancer has revealed overexpression of 
ICAM-1, prompting speculation again that this receptor is 
itself linked to the development of metastatic disease.18,30 
A 2009 study31 used four breast cancer cell lines as well as a 
single normal breast cell line and demonstrated ICAM-1 and 
DAF overexpression on malignant cells in comparison to the 
normal line. Antitumor activity was observed in vitro, and 
mice injected with tumor cells to induce metastatic disease, 
treated with CVA21, showed no detectable metastases after 
42 days, while untreated controls developed heavy tumor 
burden. Furthermore, mice with tumor xenografts treated 
with a single injection of intravenous CVA21 had reduced 
tumor burden compared to controls.
Prostate cancer
As with the other cancers discussed above, malignant pros-
tate cells displayed elevated levels of ICAM-1 and DAF;32 
ICAM-1 was absent from normal prostatic epithelium.33 
One study used three prostate cancer cell lines, two of which 
expressed high levels of ICAM-1, while the third expressed 
relatively low ICAM-1 but increased DAF.34 Lysis was 
observed on treatment with CVA21 in vitro, though this was 
significantly reduced when ICAM-1 expression was low. An 
adapted variant of CVA21, CVA21-DAFv, which internalizes 
through the DAF receptor,16 demonstrated more lysis against 
the low ICAM-1 cell line, providing further evidence that 
receptor expression and virus internalization are key factors 
in conferring sensitivity to CVA21. In fact, CVA21-DAFv 
achieved more lysis across all three lines at lower viral doses 
than CVA21, perhaps through additive utilization of both 
DAF and ICAM-1 receptors. In vivo, mouse prostate tumor 
xenograft models demonstrated that systemic administration 
of CVA21 and CVA21-DAFv achieved tumor regression. 
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The authors also noted that high viral titers of CVA21 and 
CVA21-DAFv persisted in mice with no perceivable tumor 
burden at the time of sacrifice, and postulated that the viruses 
may be capable of active replication in micrometastases, 
although this finding could alternatively be related to viral 
persistence in immunocompromised hosts.
Lung cancer
Lung tumor cells have been shown to strongly express 
ICAM-1, and initial data35 showed activity of CVA21 in 
five mouse models of both non-small-cell and small cell 
lung cancers (NSCLC and SCLC, respectively). Moderate 
to high levels of ICAM-1 expression were observed, as was 
cytotoxic CVA21 replication in NSCLC and SCLC cells 
in vitro. Intratumoral administration of CVA21 in NSCLC 
xenografts in severe combined immunodeficiency (SCID) 
mice yielded oncolysis, reduced tumor burden, and increased 
systemic levels of replicating CVA21 associated with tumor 
destruction.
Head and neck cancer
A Phase I study to establish preliminary safety and indica-
tions of efficacy of CVA21 in ICAM-1- and DAF-expressing 
squamous cell cancers of head and neck was initiated in 2009, 
but subsequently discontinued due to a poor recruitment.36 
There are no further published data at present detailing the 
effect of CVA21 in head and neck malignancies; however, 
these tumors are known to express ICAM-137 and are likely 
to be regarded as a further potential candidate for CVA21 
oncolytic therapy.
Obstacles to achieving virotherapy 
with CVA21
Virus delivery and the  
tumor microenvironment
Confirming CVA21 oncolysis in patients remains a priority 
for clinical trials, and as such, intratumoral delivery strate-
gies continue to predominate trial design. This accounts, in 
part, for the important role for melanoma in both in vitro 
and in vivo investigations, as cutaneous lesions of this 
disease are readily accessible for injected virotherapy. Yet, 
as melanoma’s propensity to metastasize demonstrates, 
therapeutic efficacy would require systemic therapy to reach 
widespread metastatic disease.
Clearly, systemic delivery will present additional hurdles 
such as, how can we ensure that systemic administration can 
satisfy the necessary, if as yet notional, “viremic threshold” 
at the sites of disease? In addition, physiological mechanisms 
that protect us against infective agents may similarly thwart 
virus therapy, including extravasation in liver and spleen and 
the presence of NABs, as discussed below. Such mechanisms 
may need to be subverted or circumvented in order to opti-
mize results with systemic therapy, and much discussion has 
already been dedicated to how this might be achieved.4
Meanwhile, the local tumor environment presents 
another range of challenges. Dense connective tissue 
within the tumor may impede passage of the virus,38 and 
additional features of tumors, such as poor lymphatic flow, 
tend to combine with this dense architecture to elevate 
interstitial fluid pressures, thus mitigating virus diffusion. 
Strategies that could help facilitate virus spread through 
the tissue include disruption of collagen synthesis using 
the angiotensin II blocking drug Losartan and disruption 
of the extracellular matrix with injected hyaluronidase. 
Furthermore, vascular permeability can be enhanced by 
administration of cytokines such as interleukin 2, tumor 
necrosis factor-α, and histamine as well as the effects of 
concurrent chemotherapy.4
Limitations of existing models
Oncolytic virotherapy remains in its infancy, or perhaps more 
optimistically, in its adolescence.39 Clinical trial data for CVA21, 
beyond initial safety studies, are not yet available. However, in 
initial studies of other OVs, it has been noted that the dramatic 
results heralded by in vitro and murine experimental models 
have not been achieved in human patients.36 This is not alto-
gether surprising since in vitro cultures do not resemble real 
pathophysiology, and results achieved in mouse models rarely 
yield equivalent results in human subjects. Importantly, research-
ers have relied upon SCID mice xenografts with different tumor 
models to study CVA21, and it is not clear if the reduced tumor 
burden achieved in these models would be reflected in mice 
or humans with an intact immune system. This is particularly 
important because oncolytic virotherapy is thought to be medi-
ated, at least in part, by the generation of antitumor immunity, 
which is not possible in immunocompromised mouse models. 
Unfortunately, immunocompetent animal models are not avail-
able to adequately mimic human infection with these viruses,36 
although in vitro human models of oncolytic virus-induced 
immunity may be informative.40,41 Moreover, the xenografting 
of tumor tissue into mice does not accurately mimic the natural 
pathology of oncogenesis. The desire to develop more plausible 
models, including translational clinical trials incorporating 
biological endpoints, has been expressed and may be crucial 
to elucidating a more representative picture of the interactions 
between the host immune system, tumor, and CVA21.6
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Immunity: challenges and possible solutions
The way in which the human immune system interacts with 
CVA21 will be a crucial determinant of its success or failure. 
Host NABs pose a problem that may undermine the efficacy 
of CVA21 and other viruses in clinical practice. CVA21 is a 
wild-type virus to which significant numbers of the population 
have already developed NABs following prior exposure, and 
in virus-naive individuals, NABs will inevitably be rapidly 
produced by a competent immune system upon initial CVA21 
treatment. This could particularly limit the efficacy of systemic 
delivery and the ability of CVA21 to reach disseminated 
metastatic disease, since circulating virus will be vulner-
able to a plethora of antiviral immune effector mechanisms 
including lymphocytes, macrophages, complement, and virus 
sequestration within the liver.6,42 Nevertheless, the extent to 
which the therapeutic effect of CVA21 may be disrupted by 
NABs in patients is as yet unclear. The experience of pre-
clinical and human trials with other OVs suggest that the role 
of NABs may vary greatly, depending on the virus and the 
model used.6 Reovirus, for example, has been shown to persist 
within resected colorectal cancer liver metastases following 
systemic delivery to patients, despite the presence of NABs 
in the circulation prior to treatment.43
The extent to which host immunity may reduce or 
enhance the efficacy of CVA21 remains to be seen. If anti-
viral immunity does undermine the effectiveness of CVA21, 
two strategies have been proposed as potential solutions: 
suppressing the host immune response or enabling the virus 
to evade immune recognition.36 The first option is to modu-
late the immune response prior to administration; this has 
been achieved in preclinical studies by combination with 
cyclophosphamide or other chemotherapeutics, which as 
immunosuppressants can inhibit the production of NABs.44–47 
Conversely, immunosuppression may not be helpful if virus-
activated innate or adaptive immune effector cells contribute 
significantly to overall therapy, as is the case for other OVs 
but remains unknown for CVA21.6
An alternative strategy is to extend the therapeutic window 
before NABs prevent oncolysis by using a combined approach, 
deploying different coxsackie virus serotypes sequentially. 
Such viruses would share the ability of CVA21 to interact with 
the receptors ICAM-1 and DAF but remain active until the 
generation of specific NABs. This “multivalent” approach has 
been demonstrated in principle with group A coxsackie viruses 
13, 15, and 18, showing they share the oncolytic properties 
of CVA21 without being susceptible to CVA21-specific 
NABs.28 This method may extend the therapeutic window, but 
such gains remain limited as NABs will inevitably develop. 
Interestingly, one study in which virus capsids were switched 
suggested that efforts to preclude NAB propagation did not 
enhance efficacy48 and may be of limited benefit.
Another approach is to conceal the virus within carrier 
cells (such as different immune effectors, irradiated tumor 
cells, or stem cells), which have sometimes been called 
“Trojan horses.” For example, vesicular stomatitis virus 
can reach disseminated disease after systemic delivery on 
irradiated vesicular stomatitis virus-infected murine colon 
carcinoma cells49 and dendritic cells can “hide” reovirus from 
the neutralizing effects of NABs.39 However, such ex vivo 
cell-based delivery strategies have the disadvantage of being 
clinically complicated and expensive. An alternative approach 
relies upon synthetic coating of the OV with a chemical com-
pound, concealing the surface of the virus to avoid destruc-
tion by NABs and activation of the complement system. For 
example, adenovirus coated with multivalent copolymers of 
poly N-(2-hydroxypropyl) methacrylamide evaded destruction 
by NABs50 and caused higher systemic virus levels by avoiding 
viral uptake in the liver.51 The efficacy of such concealment 
strategies for CVA21 has not yet been addressed.
A further strategy developed to evade immunological 
destruction involves abandoning the full virus altogether. 
Infectious ribonucleic acid (INA) encoding CVA21 RNA 
offers an alternative vector. INA can achieve regression of 
myeloma xenografts in mice comparable to that achieved by 
the virus itself, although toxicity in the form of myositis was 
seen. CVA21 may be particularly suitable for INA encoding, 
as it is a small picornavirus, while other OVs are relatively 
large by comparison.42 A potential advantage of using smaller 
molecules, such as picornavirus INA, is that it may extravasate 
relatively easily from circulation into tumor42 compared to 
larger viral vectors,52,53 although this barrier may be mitigated 
by the tendency of tumors to be more permeable (or “leaky”) 
than healthy tissue. Techniques have been explored to enhance 
extravasation of OV from the circulation to the tumor; these 
include preadministration of interleukin 2, tumor necrosis 
factor-α, and histamine and bradykinin analogues to increase 
the tumor permeability.4 Again, the relevance to CVA21 of 
such findings remains to be determined.
Safety, tolerability, and improving 
specificity
In general, oncolytic virotherapies are well tolerated, 
even at high doses,9 and few serious toxicities have been 
observed during Phase I dosing and safety trials.36 The 
early concerns from some preclinical models, which 
showed significant myositis29 following CVA21 treatment 
in SCID mice,29 have not translated into immunocompetent 
humans, at least upon multiple intratumoural injections and 
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single-dose intravenous delivery.54 Potential respiratory 
or myositic involvement may be of more significance in 
multi-dose intravenous delivery of CVA21, highlighting the 
importance of conducting appropriate early stage Phase I 
signal-seeking and tolerability studies, which began enroll-
ment in January 2014.
The experience of intravenous adenovirus, reovirus, 
and vaccinia administration suggests that where flu-like 
symptoms develop, using acetaminophen (paracetamol) 
or nonsteroidal anti-inflammatory drugs, together with the 
desensitization that occurs with gradually increasing doses, 
increases the tolerability of these agents.55 As the oncolytic 
virotherapy field progresses, other techniques to improve 
tumor selectivity will hopefully reduce generalized side 
effects of viremia. For example, one such approach has 
engineered CVA21 to express muscle-specific microRNAs, 
thereby reducing viral replication in muscle tissue and 
enhancing tumor specificity. Destabilizing the viral genome 
by microRNA target insertion provides a novel strategy 
for improved target specificity, reducing nonspecific side 
effects.57 Importantly, this paper utilized SCID mice, which 
are severely immunecompromised, hence the relevance of 
muscle paralysis and nonspecific viral replication warrants 
further investigations in immunocompetent preclinical mod-
els and early stage clinical trials.
Discussion: what lies ahead for 
CVA21?
As OVs including CVA21 continue their journey from labora-
tory modeling to clinical trials, a picture of how such agents 
may be applied in oncology practice is slowly emerging. Studies 
showing additive or even synergistic effects with conventional 
anticancer agents (chemotherapy and radiotherapy)57,58 are 
guiding the most practical path to integration with current clini-
cal practice. However, these combination approaches may not 
provide optimal conditions for the success of OVs, including 
CVA21, which may rely on the development of both innate 
and/or adaptive antitumor immunity, which are undoubtedly 
suppressed by many chemotherapeutic agents. Combination 
strategies, however, do align with the pragmatic recognition 
that OVs are likely to confer, at best, only marginal benefit 
alone, while offering significant improvements together with 
other treatment modalities.
CVA21 is at an early stage of preclinical and clini-
cal development, and many questions remain about the 
mechanisms of CVA21 efficacy and toxicity and whether 
CVA21 can target chemotherapy/radiotherapy resistant 
cells. Importantly, the answers to all of these questions could 
facilitate the development of this agent and help optimize 
therapy for different types/stages of malignant disease. The 
importance of host antitumor immunity for the therapeutic 
efficacy of OV is increasingly recognized, and very little is 
known about the interaction of CVA21 with different immune 
effectors. To exploit fully the oncolytic and immune potential 
of CVA21, a full understanding of both antiviral and anti-
tumor responses is essential. Novel immune modulators are 
currently an exciting area in cancer research, particularly with 
the success of ipilimumab for the treatment of melanoma.59 
The next generation of blocking antibodies (anti-programmed 
cell death 1 [PD-1]/anti-PD-1ligand [L]) are currently in 
early phase clinical testing. The potential of OVs in combi-
nation with such immunomodulatory therapeutics is widely 
anticipated and may provide the path to success for oncolytic 
virotherapy as viral replication/spread and direct oncolysis 
may be limited in immunocompetent hosts.
As our knowledge of the tumor microenvironment and 
its role in tumor growth is expanding, it is important to 
consider the effect of OVs on different immune effector 
cells and the supporting tumor infrastructure. It is possible 
that OVs, as potent immune “danger signals,” could either 
reverse the immunosuppressive tumor microenvironment 
or even promote tumor growth by the secretion of inflam-
matory cytokines. In addition, evaluation of viral receptor 
expression on primary fresh tumor is essential, as cell lines 
provide a limited understanding of the biology of the disease. 
More innovative research using three-dimensional culture 
systems and primary tumor/stromal cells to better mimic 
the tumor environment in patients is required to unravel the 
true potential of oncolytic virotherapy.
The antiviral immune response could limit the efficacy of 
oncolytic virotherapy, with NABs restricting tumor access, 
particularly after systemic delivery. Delivery strategies 
have been investigated to optimize viral delivery and evade 
immune recognition; however, recent studies suggest that 
viruses may be carried and protected from neutralization 
by blood cells after systemic delivery.42 Furthermore, pre-
liminary data from our and other laboratories suggest that 
in contrast to the accepted dogma that NABs will inhibit 
antitumor responses, NABs may actually improve therapy in 
some contexts. This hypothesis requires further investigation 
but demonstrates how limited our knowledge and understand-
ing is regarding how OVs may interact with the host immune 
system. It is important to continue the parallel, rather than 
sequential, development of OVs in the laboratory and clinic, 
as this will rapidly increase our knowledge and understanding 
of oncolytic virotherapy, will ensure that any sign of clinical 
efficacy would be observed sooner rather than later, and will 
facilitate the development of optimal therapeutic strategies. 
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Thus, early results from the Phase II CALM study indicating 
a 26.7% overall response rate in injected lesions, as reported 
at the World Congress of Melanoma in 2013, will arouse 
interest from clinicians and researchers worldwide.
Whatever the eventual role of CVA21, as for any new 
agent, the results of Phase I, II, and III clinical trials will 
 sultimately determine its application in routine clinical 
practice. A Phase II trial of intratumoral injection of CVA21 
in melanoma is underway while a Phase I trial of intrave-
nous administration is imminent. Potentially, these trials 
will reveal a role for the virus in all ICAM-1- and DAF-ex-
pressing malignancies. The current journey of CVA21, from 
eliciting its receptor-based mechanisms of action through 
to application in cancer therapy, is proving an informative 
example of the current translation of oncolytic virotherapy 
from laboratory to clinic. The speed with which CVA21 is 
moving into clinical testing, without the need for exhaustive 
preclinical testing in models that are at best a poor mimic 
of cancer in patients, will help the visibility of OVs within 
the wider, nonresearch-based clinical oncology community. 
Future studies with this agent are required to support the 
development of CVA21 as a novel anticancer agent and to 
exploit tumor and immune characteristics for optimal thera-
peutic gain in the treatment of malignant disease.
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